Candida auris: epidemiological situation, laboratory capacity and preparedness in the European Union and European Economic Area*, January 2018 to May 2019

Euro Surveill. 2020 Mar;25(12):2000240. doi: 10.2807/1560-7917.ES.2020.25.12.2000240.

Abstract

Between January 2018 and May 2019, 349 cases of Candida auris were reported in the European Union/European Economic Area*, 257 (73.6%) colonisations, 84 (24.1%) bloodstream infections, seven (2.0%) other infections and one case of unknown infection/colonisation status (0.3%). Most cases (97.1%, n = 339) were reported from Spain or the United Kingdom, but also for the first time in Greece, the Netherlands and Poland. Laboratory capacity and preparedness has improved since January 2018.

Keywords: Candida auris; epidemiology; laboratory capacity; preparedness.

MeSH terms

  • Antifungal Agents / pharmacology
  • Antifungal Agents / therapeutic use
  • Candida / drug effects
  • Candida / isolation & purification*
  • Candidiasis / diagnosis*
  • Candidiasis / drug therapy
  • Candidiasis / epidemiology
  • Communicable Diseases, Emerging / epidemiology
  • Disease Outbreaks
  • Drug Resistance, Multiple, Fungal
  • Europe / epidemiology
  • European Union
  • Humans
  • Infection Control
  • Microbial Sensitivity Tests

Substances

  • Antifungal Agents